Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

The total market for glucagon products for hypoglycaemia has been estimated to be worth around $2 billion worldwide. Lilly acquired rights to Baqsimi from Canadian biotech Locemia Solutions in ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Hanmi Pharmaceutical develops obesity drugs to increase muscle while reducing fat Hanmi Pharmaceutical pioneers innovative ...

A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), ...

inhibits β-cell apoptosis and inhibits glucagon secretion. Two such drugs are currently approved — exenatide (Byetta; Amylin/Eli Lilly and Company) and liraglutide (Victoza; NovoNordisk ...

Both companies are competing in GLP-1 (Glucagon-like Peptide-1) receptor agonists that help in promoting weight loss. BioSpace reported that Eli Lilly faces fierce competition from Novo Nordisk ...

finds that among glucagon-like peptide 1 (GLP-1) receptor agonists and co-agonists on the market or still being investigated, the experimental drug retatrutide (Eli Lilly and Company) produces the ...